Previous close | 42.75 |
Open | 42.54 |
Bid | 42.44 x 1000 |
Ask | 43.81 x 800 |
Day's range | 42.43 - 43.05 |
52-week range | 34.74 - 47.70 |
Volume | |
Avg. volume | 1,272,273 |
Market cap | 9.516B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | 28.10 |
EPS (TTM) | 1.53 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | 1.28 (2.94%) |
Ex-dividend date | 30 Jan 2024 |
1y target est | 51.05 |
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost‑effective diagnosis of complex syndromes placed worldwide by the end of 2023Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: Q
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.